Pancreatic Cancer Research

Clinical trialPhase 2Completed

Cabozantinib and Pembrolizumab in Metastatic Pancreas

Phase II Clinical Trial Evaluating Cabozantinib and Pembrolizumab in Metastatic Pancreatic Cancer

Outcome
Results posted; single-arm, no comparison
Phase
Phase 2
Status
Completed
Study type
Interventional
Start
4 January 2022
Ended
5 November 2024
Enrollment
21 participants
Sites
1
Primary outcomes
Progression-free Survival
Sponsor type
Academic / other
Results posted
19 November 2025
Last update
19 November 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 19 November 2025
PFS
Progression-free SurvivalCabozantinib and pembrolizumab: 2 of 21Values: ParticipantsTime frame: 1 yearNo analysis posted for this outcome (outcome 1)
Participants
Cabozantinib and pembrolizumab: 21 started, 2 completed
Serious adverse events
Cabozantinib and pembrolizumab: 13 of 21Participants with at least one serious adverse event, of those at risk, as posted
4 secondary outcomes
Number of Participants With Response to Therapy
Cabozantinib and pembrolizumab 1/21 [Participants]
Number of Participants With Complete Response
Cabozantinib and pembrolizumab 0/21 [Participants]
Number of Participants With Partial Response
Cabozantinib and pembrolizumab 1/21 [Participants]
Overall Participant Survival Rate
Cabozantinib and pembrolizumab 2/21 [Participants]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Progression-free Survival [1 year]. Count Of Participants, Participants. Cabozantinib and pembrolizumab (n=21): 2.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Participants With Response to Therapy [1 year]. Count Of Participants, Participants. Cabozantinib and pembrolizumab (n=21): 1.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Participants With Complete Response [1 year]. Count Of Participants, Participants. Cabozantinib and pembrolizumab (n=21): 0.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Participants With Partial Response [1 year]. Count Of Participants, Participants. Cabozantinib and pembrolizumab (n=21): 1.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Participant Survival Rate [1 year]. Count Of Participants, Participants. Cabozantinib and pembrolizumab (n=21): 2.